摘要
随着医学诊疗水平的提高,射频消融在治疗原发性肝癌的临床应用和基础研究方面都取得飞速进展,发挥着越来越重要的作用:(1)射频消融治疗原发性肝癌的10年总生存率为27.3%-46.1%,对于肿瘤单发且最大径≤3 cm的HCC患者,10年总生存率可达74%,生存结果与手术切除相似;(2)射频消融联合其他治疗等可以扩大消融治疗的适应证,使患者生存获益;(3)建立预测射频消融治疗原发性肝癌的预后模型,可指导制定治疗和随访策略,为临床个体化诊疗提供重要依据.
With the improvement of technology and diagnostic level,radiofrequency ablation(RFA)has made rapid progress in the treatment of primary hepatocellular carcinoma(HCC)in the past two decades.Especially,the overall survival after the treatment of small HCCs by RFA can be comparable to that achieved by hepatic resection.The 10-year survival rates of RFA for HCC were 27.3%-46.1%,and for solitary HCC less than 3 cm,the 10-year survival rate is about 74.0%.RFA combined with other therapies can expand the indications of RFA treatment and benefit the survival of patients with HCC.The prognostic model of RFA for HCC provides a powerful tool for individualized clinical diagnosis and treatment.
作者
白秀梅
杨薇
Xiu-Mei Bai;Wei Yang(Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Ultrasound,Peking University Cancer Hospital and Institute,Beijing 100142,China)
出处
《世界华人消化杂志》
CAS
2021年第13期677-683,共7页
World Chinese Journal of Digestology
基金
国家自然科学基金,No.81773286和No.81971718
首都卫生发展科研专项,No.2018-2-2154
北京市百千万人才工程,No.2020A47.
关键词
原发性肝细胞癌
射频消融
预测模型
预后因素
Primary hepatocellular carcinoma
Radiofrequency ablation
Prognostic nomogram
Prognostic factors